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Abstract: 
Purpose-It is unclear whether sex hormone profiles obtained in two consecutive months are 
consistent within women. Month-to-month consistency in daily, nadir, peak and mean hormone 
concentrations during the early follicular and luteal phases in recreationally active, young 
eumenorrheic women was prospectively examined.  
Methods-60 healthy, non-smoking women who reported normal and consistent menstrual cycles 
lasting 26–32 days for the past 6 months were followed prospectively to obtain serum samples 
for the first 6 days of menses and for 8 days after a positive ovulation test over two consecutive 
months. Month-to-month consistency of daily concentrations of oestradiol (pg/ml), progesterone 
(ng/ml), testosterone (ng/dl), sex hormone-binding globulin (nmol/l) and free androgen index 
were determined using linear mixed models. Month-to-month consistency in nadir, peak and 
mean concentrations were then assessed using intraclass correlation coefficients and SEM to 
more precisely examine intraindividual consistency.  
Results-Linear mixed models revealed stable hormone concentrations across cycles and cycles 
by day. Reliability estimates for nadir, peak, mean menses and mean postovulatory 
concentrations range from 0.56 to 0.86 for oestradiol, 0.44 to 0.91 for progesterone, 0.60 to 0.86 
for testosterone, 0.88 to 0.97 for sex hormone-binding globulin and 0.78 to 0.91 for free 
androgen index.  
Conclusions-Hormone profiles were reproducible over two consecutive months. To reduce 
month-to-month intraindividual variations and improve measurement consistency, it is 
recommended that multiple samples be taken over consecutive days as opposed to a single 
sample.  
 
Article: 
Variations in sex hormone concentrations in young, physically active women may be associated 
with the risk of non-contact anterior cruciate ligament (ACL) injury. Studies report a greater 
number of injuries than expected during the perimenstrual1–3 and periovulatory4 5 days, whereas 
others generally identified the follicular phase as being the phase of higher risk.6 7 These studies 
collected a single sample (blood or urine) shortly after the injury (range 2 h7 to 72 h2), making it 
difficult to identify the specific time in a particular phase when injury occurred (ie, whether 
hormone levels were rising, falling or near their peak). Other work suggests a time delay 
between when hormone concentration change and when soft tissues change (eg, laxity),8 
emphasising the importance of documenting hormone profiles in the days preceding the injury. 
Because ACL injuries occur infrequently, retrospective studies are the most practical research 
design to comprehensively examine hormone profiles associated with injury risk. For 
retrospective studies to be valid, establishing consistency of hormone profiles month to month is 
both necessary and paramount as a first step. The application of the present data may also be 
useful in a research setting when projecting hormonal phases for future data collections.  
 
Although the typical hormone profile of a 28-day cycle is well established, women have 
substantial variations from this typical profile in their cycle length (both follicular and luteal 
phases), the timing of changes in one hormone relative to another, the day of ovulation and 
absolute change in hormone concentrations.8–12 Although this variability is substantially greater 
between women than within a woman from one month to the next, some variations within a 
woman also occur.13 Therefore, it is important to quantify the magnitude of these intraindividual 
variations to determine how consistent an individual's hormone profile will be from one month to 
the next. We examined the month-to-month consistency in daily, nadir, peak and mean hormone 
profiles during the first 6 days of the early follicular phase and the first 8 days of the early luteal 
phase for two consecutive cycles in young, normal menstruating women. Our expectation was 
that sex hormone profiles would be highly reproducible from one month to the next.  
 
METHODS 
Serum samples were obtained prospectively from 60 women (age 21.7 (2.6) years, height 163.9 
(6.5) cm and weight 60.3 (8.6) kg), participating in a larger project examining the effects of sex 
hormone-mediated changes in knee laxity on knee joint function. Subjects were included if they 
self-reported regular physical activity between 2.5 and 10 h per week for the past 3 months, 
normal menstrual cycles lasting 26–32 days with consistent cycle lengths varying no more than 
±1 day each month for the past 6 months, no use of oral contraceptives or other hormone-
stimulating medications for the past 6 months, and no history of pregnancy. Subjects with a body 
mass index >30 (BMI; weight/height2), a previous history of knee ligament injury, or who 
smoked were excluded. At the time of this study, 67 female subjects had been enrolled in the 
larger study. However, seven were excluded because of incomplete data (four voluntarily 
withdrew; three lacked a positive ovulation test). All participants were informed of the study 
procedures and signed a consent form approved by the university's Institutional Review Board 
for the Protection of Human Subjects.  
 
Procedures 
Serum (10 cc) was collected daily using standard venipuncture procedures during the first 6 days 
of the early follicular phase (day 1 identified as the day immediately after the onset of menses 
per self-report; labelled M1–M6) and for the first 8 days of the early luteal phase (day 1 
identified as the first day after evidence of ovulation; labelled L1–L8) for two consecutive 
months. To control for diurnal fluctuations in hormone concentrations, all samples were obtained 
in the morning hours (07:00–09:00, usually within ±30 min for each participant) before physical 
activity. To estimate the day of ovulation, participants used a commercially available ovulation 
kit (CVS One Step Ovulation Predictor (sensitivity 20 mIU ml luteinizing hormone, accuracy 
99%; CVS Corporation, Woonsocket, Rhode Island, USA) starting with day 8 of their menstrual 
cycle. Participants were instructed to maintain normal activity patterns and avoid excessive 
physical activity for 2 days before any testing and to defer their normal activity until their serum 
was collected on each test day. Subjects were also instructed to abstain for alcohol consumption 
for 24 h prior and throughout each testing block. Participants completed a daily questionnaire to 
ensure study compliance.  
 
Figure 1: Daily mean early follicular (M1–M6) and early luteal (L1–L8) oestradiol (A, B), 
progesterone (C, D) and testosterone (E, F) concentrations over two consecutive months for all 
subjects (N=60, left column) and those with anovulatory cycles removed (n=49, right column).  
 
 
Assays 
Blood samples were separated and stored at −80°C and shipped to a Ligand Assay and Analysis 
Core Laboratory to assay serum levels of oestradiol, progesterone, testosterone and sex hormone-
binding globulin (SHBG). All samples for a given subject were analysed within the same assay 
test kit. Oestradiol was assayed using a double-antibody radioimmunoassay assay (DSL-4400; 
Beckman Coulter, Webster, Texas, USA), and progesterone and testosterone concentrations were 
assayed using Coat-A-Count radioimmunoassay assays (TKPG-2 and TKTT-2; Siemens Medical 
Solutions Diagnostics, Los Angeles, California, USA). SHBG was assayed using the Immulite 
chemiluminescent technology (LKSH5; Siemens Medical Solutions Diagnostics). Free androgen 
index (FAI) was calculated based on testosterone and SHBG levels (FAI=total testosterone 
(nmol/l)/SHBG (nmol/l)). Mean percent intra-assay and inter-assay coefficient of variations 
(%CV), respectively, were 5.2% and 10.6% for oestradiol, 4.1% and 6.4% for progesterone, 
3.4% and 8.1% for testosterone, and 2.4% and 5.8% for SHBG. Assay sensitivities were 10 
pg/ml (oestradiol), 0.1 ng/ml (progesterone), 10 ng dl (testosterone) and 0.2 nmol/l (SHBG).  
 
Figure 2: Daily mean early follicular (M1–M6) and early luteal (L1–L8) serum hormone-
binding globulin (SHBG) (A, B) and free androgen index (C, D) concentrations over two 
consecutive months for all subjects (N=60, left column) and those with anovulatory cycles 
removed (n=49, right column).  
 
 
Although oestradiol, progesterone and, to a lesser extent, testosterone have been the primary 
hormones of interest when describing the hormone profile of a particular woman, the capacity of 
these sex steroids to exert their effect on soft tissues is dependent on the amount of each sex 
hormone that is freely circulating (ie, biologically active).14 15 SHBG is considered to be the 
major regulator of plasma free concentrations for oestradiol and testosterone because it has a 
high binding affinity for these hormones. Although research suggests that little if any change in 
SHBG concentrations occur across the menstrual cycle16 (thus the freely circulating 
concentration of oestradiol and testosterone), we felt it was important to confirm the extent to 
which SHBG concentrations (and similarly a measure of the biologically available fraction of a 
hormone, ie, FAI in this study) vary from cycle to cycle because this would have further 
implications on the ability to reliably predict hormone concentrations retrospectively.  
 
Data analysis 
To examine the general consistency of daily changes in hormone concentrations during the 6 
menses days (M1–M6) and the 8 postovulatory days (L1–L8) from one month to the next, we ran 
separate linear mixed models (Proc Mixed, Statistical Analysis System V.9.1.2; SAS Institute, 
Cary, North Carolina, USA) for each of the hormones, with the hormone as the dependent 
variable and cycle, day, and the cycle-by-day interaction as the independent variables. 
Significance was set a priori at p<0.05. To more closely examine the intraindividual month-to-
month consistency of hormone profiles, intraclass correlation coefficient formula 2,1 (ICC2,1)17 
compared cycles 1 and 2 on absolute nadir and peak hormone concentrations obtained during 
M1–M6 and during L1–L8, respectively. We then used ICC formula 2,k17 to compare cycles 1 
and 2 on mean concentrations obtained across M1–M6 and L1–L8. For each reliability estimate, 
the SEM was calculated (SD√(1−ICC)).18 
 
Once the serum was assayed, 11 women (18%) were found to have anovulatory cycles in one 
(n=8) or both (n=3) months, defined as a luteal phase progesterone level that did not exceed 3 
ng/ml.19 20 Therefore, we ran all our analyses on both the entire data set (N=60) and then limited 
analyses to those with two confirmed ovulatory cycles (n=49) to determine the effect of 
anovulatory cycles on measurement consistency. Our rationale to include anovulatory cycles is 
that it may not always be possible to confirm the presence or absence of anovulatory cycles in 
retrospective studies.  
 
RESULTS 
Comparison of daily hormone concentrations between cycles. The daily means and SD of the 
five hormone concentrations during M1–M6 and L1–L8 over two cycles are shown in figs 1 and 
2. Table 1 reports the linear mixed model results comparing hormone concentrations between 
cycles, days and cycle by days. During M1–M6, all hormone concentrations differed between 
individual days, except for SHBG, which remained stable (p>0.117). In all cases, daily changes 
in hormone concentrations were generally consistent between cycles because no significant 
differences in hormone concentrations by cycle or cycle by day were observed. When examining 
L1–L8, all hormone concentrations differed between individual days (all p<0.004), and these 
differences were also consistent across cycle and cycle by day. Results did not change when 
anovulatory cycles were removed.  
 
Consistency of nadir, peak and mean hormone concentrations. Table 2 lists the means, SD 
and reliability estimates examining the month-to-month consistency in absolute nadir and peak 
hormone concentrations. ICCs for the entire sample ranged from 0.58 to 0.88 for nadir and 0.44 
to 0.89 for peak concentrations. Although ICC values were consistently high for SHBG and FAI 
(0.78–0.89), estimates were lower for oestradiol, progesterone and testosterone levels (0.44–
0.71). Analyses of the sources of variance and SEM values for these hormones indicate that the 
lower ICCs were primarily due to random error rather than systematic differences in 
concentrations between cycles. When anovulatory cycles were removed, ICC values were 
similar, except for nadir and peak oestradiol levels, where the ICC values decreased somewhat 
but the SEMs stayed relatively unchanged.  
Table 1: ANOVA results for sex steroid hormones when all subjects were included in the 
analysis and when analysis included only subjects with two ovulatory cycles  
  p Value 
 Effect All subjects (N=60) Ovulatory cycles (n=49) 
Oestradiol 
 Menses Cycle 0.691 0.880 
Day <0.001* <0.001* 
Cycle×day 0.201 0.335 
 Postovulatory Cycle 0.932 0.885 
Day 0.004* 0.003* 
Cycle×day 0.353 0.145 
Progesterone 
 Menses Cycle 0.480 0.391 
Day <0.001* <0.001* 
Cycle×day 0.395 0.341 
 Postovulatory Cycle 0.657 0.561 
Day <0.001* <0.001* 
Cycle×day 0.842 0.247 
Testosterone 
 Menses Cycle 0.058 0.243 
Day <0.001* <0.001* 
Cycle×day 0.597 0.807 
 Postovulatory Cycle 0.387 0.077 
Day <0.001* <0.001* 
Cycle×day 0.498 0.380 
SHBG 
 Menses Cycle 0.749 0.518 
Day 0.117 0.374 
Cycle×day 0.321 0.696 
 Postovulatory Cycle 0.820 0.874 
Day <0.001* <0.001* 
Cycle×day 0.761 0.416 
FAI 
 Menses Cycle 0.052 0.313 
Day <0.001* <0.001* 
Cycle×day 0.760 0.834 
 Postovulatory Cycle 0.222 0.182 
Day <0.001* <.0001* 
Cycle×day 0.485 0.415 
ANOVA, analysis of variance; FAI, free androgen index; SHBG, sex hormone-binding globulin. 
Analysis was separated by phase of the menstrual cycle (menses and postovulatory). 
* p<0.05.  
 
 
Table 3 lists the means, SD and reliability estimates examining the month-to-month consistency 
in the mean hormone concentrations collapsed across M1–M6 and across L1–L8. These analyses 
revealed substantially stronger ICCs and improved precision (SEMs) compared with those 
obtained for peak and nadir concentrations. ICC values ranged from 0.81 to 0.97 (and were 
similar with and without anovulatory cycles), with the exception of mean postovulatory 
progesterone levels (0.54–0.59), which were more variable month to month.  
 
 
 
 
 
 
 
Table 2: Mean, SD, ICC and SEM comparing month-to-month consistency in absolute nadir 
(from the 6 days of menses) and peak (from the 8 postovulatory days) sex hormone 
concentrations for all subjects and with anovulatory cycles removed  
 Cycle 1  Cycle 2   
 Mean (SD)  Mean (SD) ICC SEM 
All subjects (N=60)  
 Nadir (menses) values  
  Oestradiol (pg/ml) 37.5 (14.0)  35.4 (15.2) 0.58 9.8 
  Progesterone (ng/ml) 0.6 (0.3)  0.6 (0.3) 0.67 0.2 
  Testosterone (ng/dl) 22.6 (11.4)  20.2 (10.2) 0.60 7.2 
  SHBG (nmol/l) 60.8 (24.2)  62.9 (23.6) 0.88 8.4 
  FAI 1.3 (0.9)  1.1 (0.8) 0.78 0.4 
 Peak (postovulatory) values  
  Oestradiol (pg/ml) 208.7 (92.5)  209.0 (111.2) 0.56 73.6 
  Progesterone (ng/ml) 14.6 (7.8)  13.9 (7.9) 0.44 5.9 
  Testosterone (ng/dl) 49.2 (17.4)  48.7 (19.6) 0.71 10.5 
  SHBG (nmol/l) 80.0 (30.1)  80.9 (33.8) 0.89 11.4 
  FAI 2.9 (1.6)  2.8 (1.5) 0.82 0.7 
Ovulatory cycles only (n=49)  
 Nadir (menses) values  
  Oestradiol (pg/ml) 36.0 (12.7)  34.3 (14.7) 0.48 10.6 
  Progesterone (ng/ml) 0.6 (0.3)  0.6 (0.2) 0.66 0.2 
  Testosterone (ng/dl) 22.6 (10.9)  21.0 (9.7) 0.60 6.9 
  SHBG (nmol/l) 59.5 (23.6)  60.7 (22.2) 0.86 8.7 
  FAI 1.3 (0.9)  1.2 (0.8) 0.82 0.4 
 Peak (postovulatory) values  
  Oestradiol (pg/ml) 214.1 (83.1)  211.1 (95.3) 0.38 74.8 
  Progesterone (ng/ml) 16.5 (6.7)  15.7 (6.5) 0.41 5.1 
  Testosterone (ng/dl) 48.5 (16.7)  46.6 (15.6) 0.73 8.6 
  SHBG (nmol/l) 77.7 (28.4)  78.0 (31.5) 0.87 11.3 
  FAI 3.0 (1.7)  2.9 (1.6) 0.85 0.7 
FAI, free androgen index; ICC, intraclass correlation coefficient; SEM, standard error of measurement; SHBG, sex hormone-binding globulin.  
Table 3: Mean, SD, ICC (2,k) and SEM examining the consistency of mean sex hormone 
concentrations during menses (days 1–6) and postovulation (days 1–8) across two menstrual 
cycles for all subjects and with anovulatory cycles removed  
 Cycle 1  Cycle 2   
 Mean (SD)  Mean (SD) ICC SEM 
All subjects (N=60)  
 Mean menses values  
  Oestradiol (pg/ml) 55.6 (19.7)  53.7 (18.7) 0.86 7.5 
  Progesterone (ng/ml) 0.8 (0.3)  0.8 (0.3) 0.91 0.1 
  Testosterone (ng/dl) 31.6 (13.0)  29.3 (11.4) 0.81 5.7 
  SHBG (nmol/l) 69.4 (26.7)  69.8 (25.8) 0.97 4.5 
  FAI 1.8 (1.1)  1.7 (1.0) 0.90 0.3 
 Mean postovulatory values  
  Oestradiol (pg/ml) 131.0 (46.3)  131.3 (55.0) 0.82 23.2 
  Progesterone (ng/ml) 8.7 (5.0)  8.4 (5.6) 0.59 3.7 
  Testosterone (ng/dl) 35.8 (12.9)  34.7 (14.4) 0.86 5.3 
  SHBG (nmol/l) 61.4 (21.0)  71.0 (27.9) 0.90 8.8 
  FAI 2.1 (1.2)  2.0 (1.0) 0.91 0.4 
Ovulatory cycles only (n=49)  
 Mean menses values  
  Oestradiol (pg/ml) 55.0 (19.2)  53.2 (17.8) 0.83 8.0 
  Progesterone (ng/ml) 0.8 (0.3)  0.8 (0.3) 0.90 0.1 
  Testosterone (ng/dl) 31.3 (11.7)  30.0 (10.9) 0.81 5.1 
  SHBG (nmol/l) 68.3 (25.9)  67.5 (24.1) 0.97 4.5 
  FAI 1.9 (1.1)  1.8 (1.0) 0.93 0.3 
 Mean postovulatory values  
  Oestradiol (pg/ml) 134.4 (40.8)  133.6 (50.4) 0.81 22.2 
  Progesterone (ng/ml) 10.0 (4.4)  9.5 (4.8) 0.54 3.3 
  Testosterone (ng/dl) 35.5 (12.5)  33.6 (11.5) 0.88 4.1 
  SHBG (nmol/l) 59.9 (19.5)  68.9 (26.6) 0.90 8.6 
  FAI 2.1 (1.3)  2.0 (1.1) 0.94 0.3 
FAI, free androgen index; ICC, intraclass correlation coefficient; SEM, standard error of measurement; SHBG, sex hormone-binding globulin.  
 
For descriptive purposes only, table 4 lists the means and SD comparing nadir, peak and mean 
hormone concentrations between women with two ovulatory cycles (OVUL, n=49), one 
ovulatory and one anovulatory cycle (OVUL/ANOV, n=8) and two anovulatory cycles (ANOV, 
n=3). Although difficult to examine statistically given the small number of women with 
anovulatory cycles, oestradiol levels appear to vary considerably when women were stratified 
based on the consistency of ovulatory versus anovulatory cycles. Specifically, women with 
anovulatory cycles had substantially lower luteal phase oestradiol levels, with the lowest levels 
observed in those with consistent anovulatory cycles. SHBG concentrations also appear to vary 
somewhat, with higher concentrations observed in women with inconsistent ovulatory cycles and 
somewhat lower concentrations in those who had consistent anovulatory cycles. Related to these 
differences in SHBG, proportional changes in FAI were observed, suggesting that the free 
fraction concentrations of these hormones may also differ between these groups.  
 
 
Table 4: Means and SDs comparing nadir, peak and mean hormone concentrations between 
women with two ovulatory cycles (OVUL, n=49), one ovulatory and one anovulatory cycle 
(OVUL/ANOV, n=8) and two anovulatory cycles (ANOV, n=3)  
  OVUL/ANOV (n=8)   
 OVUL (n=49)  OVUL cycle  ANOV cycle  ANOV (n=3) 
 Mean (SD)  Mean (SD)  Mean (SD)  Mean (SD) 
Nadir and peak values    
 Nadir (M1–M6)    
  Oestradiol (pg/ml) 36.0 (12.7)  50.9 (60.2)  43.4 (11.1)  29.4 (18.9) 
  Progesterone (ng/ml) 0.6 (0.3)  0.7 (0.4)  0.6 (0.2)  0.5 (0.2) 
  Testosterone (ng/dl) 22.6 (10.9)  24.2 (11.9)  16.6 (10.3)  17.5 (18.2) 
  SHBG (nmol/l) 59.5 (23.6  76.6 (33.0)  75.2 (26.5)  53.4 (12.2) 
  FAI 1.3 (0.9)  1.0 (0.3)  0.8 (0.5)  1.0 (1.1) 
 Peak (L1–L8)    
  Oestradiol (pg/ml) 214.1 (83.1)  261.8 (181.0)  197.1 (137.9)  92.5 (18.2) 
  Progesterone (ng/ml) 16.5 (6.7)  14.8 (7.4)  1.4 (0.5)  1.4 (0.9) 
  Testosterone (ng/dl) 48.5 (16.7)  59.0 (22.0)  60.8 (33.8)  42.1 (17.1) 
  SHBG (nmol/l) 77.7 (28.4)  105.3 (40.2)  98.0 (41.0)  61.8 (18.2) 
  FAI 3.0 (1.7)  2.6 (1.0)  2.4 (0.8)  2.8 (1.2) 
Mean values    
 Menses (M1–M6)    
  Oestradiol (pg/ml) 55.0 (19.2)  64.5 (22.3)  62.3 (17.3)  39.8 (22.1) 
  Progesterone (ng/ml) 0.8 (0.3)  0.9 (0.5)  0.8 (0.3)  0.7 (0.3) 
  Testosterone (ng/dl) 31.3 (11.7)  35.0 (14.6)  26.7 (13.4)  26.1 (22.1) 
  SHBG (nmol/l) 68.3 (25.9)  85.5 (35.4)  83.6 (31.3)  57.8 (13.2) 
  FAI 1.9 (1.1)  1.5 (0.3)  1.1 (0.4)  1.6 (1.5) 
 Postovulatory (L1–L8)    
  Oestradiol (pg/ml) 134.4 (40.8)  162.1 (74.1)  117.1 (59.2)  61.6 (14.4) 
  Progesterone (ng/ml) 10.0 (4.4)  8.0 (5.8)  1.0 (0.5)  0.9 (0.5) 
  Testosterone (ng/dl) 35.5 (12.5)  40.5 (14.8)  43.8 (24.2)  29.3 (16.4) 
  SHBG (nmol/l) 59.9 (19.5)  85.6 (32.1)  79.4 (29.9)  52.4 (13.0) 
  FAI 2.1 (1.3)  1.6 (0.4)  1.8 (0.8)  1.9 (1.1) 
FAI, free androgen index; SHBG, sex hormone-binding globulin. 
 
 
DISCUSSION 
Much of the literature on hormone repeatability focuses on older premenopausal women 
(typically 35–50 years of age) to determine whether a single hormone measure can reliably 
predict hormone exposure over time, thus future disease risk.21–25 However, in the case of ACL 
injury where acute hormone exposure is of interest, there is a need to know if hormone profiles 
obtained postinjury can adequately reflect the hormone profiles just before injury. As an initial 
step towards this effort, we quantified the consistency in hormone profiles in young, physically 
active and normal menstruating women. Our findings in a group of young, recreationally active 
eumenorrheic women revealed that daily mean hormone concentrations measured during M1–
M6 and L1–L8 varied by day as expected, but were generally stable from one month to the next. 
However, when examining intraindividual month-to-month consistency in nadir, peak and mean 
hormone concentrations, reliability estimates varied across the five hormones tested. With the 
exception of nadir and peak oestradiol (0.38–0.48 with anovulatory cycles removed) and peak 
progesterone levels (0.41 and 0.44 with and without anovulatory cycles), reliability estimates for 
all other nadir and peak hormone values ranged from 0.56 to 0.89. These estimates appear to 
represent highly reliable measures based on what has been reported in the hormone literature.22 24 
25 This is particularly true of SHBG and FAI, suggesting that the proportion of each hormone 
concentration that is biologically available is very stable from month-to-month within a woman. 
The lower reliability we observed for nadir and peak oestradiol and progesterone levels is 
consistent with previous studies in premenopausal women where a single measure of oestradiol 
and progesterone was obtained (oestradiol (0.38–0.53 for follicular measures, 0.06–0.45 for 
luteal phase measures),13 21 22 24 25 progesterone (0.29–0.54 for luteal phase measures)),22 24 
suggesting there is substantial month-to-month variations in absolute daily levels of oestradiol 
and progesterone within a woman, particularly during the postovulatory days. However, when 
concentrations are averaged over multiple days, reliability estimates improved considerably 
(table 2 vs 3). Hence, it may be necessary to take multiple samples to gain an adequate 
representation of a woman's hormone profile, particularly when examining oestradiol and 
progesterone.  
 
To fully appreciate the magnitude of this variability, the SEM provides a unit value of 
measurement precision that is based on the distribution of measurement error.26 Specifically, 
there is a 68% and 95% chance that the participant's true hormone value will fall within ±1 or ±2 
SEMs, respectively, of the value obtained from a subsequent month. In some cases, particularly 
for peak oestradiol, progesterone and testosterone levels, the SEMs seem rather large and suggest 
considerable measurement error. When these error variances are compared against the overall 
deviation and range in concentrations obtained in this cohort, SEM values generally represented 
<15% of the total range in concentrations obtained for nadir (7.0–14.5%) and peak (8.2–16.3%), 
and <10% of the total range in mean menses (3.6–7.5%) and mean luteal (6.2–11.7%) values. 
The only exception was peak progesterone levels, where the SEM represented 18–20% of the 
range in values for nadir and peak levels, and 10–19% of the range in values for mean menses 
and luteal values. As epidemiological studies often reduce hormone values to quartiles when 
classifying the association of a particular hormone with disease,22 the precision of these values 
may be acceptable. The improved measurement precision when using mean values (table 3) 
again indicates the importance of taking multiple samples to enhance the accuracy of 
determining hormone profiles in a subsequent month.  
 
Our findings also revealed that measurement consistency and precision were relatively robust to 
the presence of occasional anovulatory cycles. When women with one or both anovulatory cycles 
were removed (18% of the sample), the ICC and SEM values remained relatively unchanged 
except for nadir and peak oestradiol values (table 2). As noted in table 4, women with 
anovulatory cycles had substantially lower oestradiol levels, particularly during the luteal phase. 
Hence, the lower ICC values for oestradiol values when anovulatory cycles were removed may 
result from a lower proportion of between-subject variance. Perhaps most important is that the 
SEM values for luteal-phase oestradiol and progesterone did not improve appreciably when the 
eight subjects with inconsistent ovulatory cycles (thus inconsistent oestradiol and progesterone 
levels) were removed. This further speaks to the inherent intraindividual variation in oestradiol 
and progesterone levels, even in those with consistent ovulatory cycles.  
 
In summary, sex hormone profiles are in large part reproducible over two consecutive months in 
young, recreationally active eumonorrheic women. Although intraindividual variations exist, 
they are substantially smaller than between-subject variations. To reduce month-to-month 
intraindividual variations and improve measurement accuracy, it is recommended that multiple 
samples be taken over consecutive days as opposed to a single sample to represent a given phase. 
Furthermore, the inherent stability of SHBG values within a woman from one month to the next 
suggest that although total hormone concentrations may vary somewhat within a woman from 
one cycle to the next, the proportion of these concentrations that are biologically active should 
change very little within a woman from one cycle to the next. Although these findings support 
the feasibility of retrospectively examining relationships between hormone profiles and injury 
risk, there are important limitations to the current work. Specifically, these findings are limited to 
healthy physically active women who, by nature of the parent project, were uninjured and 
reported normal menstrual cycles lasting 26–32 days for the past 6 months and maintained a 
consistent level of activity throughout the study. Before we can study hormone profiles 
retrospectively in an injured population, the impact of the trauma and acute changes in exercise 
status as a result of the injury on hormone profile reproducibility needs to be investigated. For 
example, one study observed a relationship between physical trauma and surgical stress with 
irregular cycles postinjury27; however, these findings were not based on a young physically 
active population undergoing surgery for ligament trauma. In regards to exercise, previous 
research has shown that the intensity of physical activity may also influence menstrual cycle 
characteristics,28 and therefore a substantial modification in exercise due to injury may affect 
hormone profiles in some athletes.  
 
These findings are also limited to the reproducibility of sex steroid hormone concentrations. As 
one report noted a greater than expected risk of ACL injury near ovulation,5 and suggested that it 
may be important to also account for the gonadatropins that control ovulation and sex steroid 
secretion (follicle-stimulating hormone or luteinizing hormone) when examining injury 
susceptibility, studies examining the reproducibility of these gonadatropins should also be 
considered. Finally, it is well accepted that many competitive athletes experience irregular 
cycles, and we are not aware of studies that have examined hormone profile consistency in 
oligomenorrheic or amenorrheic female athletes. Hence, this study represents only a first step in 
understanding the feasibility of examining hormone profiles retrospectively. It is our hope that 
by first quantifying the natural intraindividual variations in hormone concentrations with these 
factors controlled, future work can better quantify any additional variability associated with these 
other factors. Specifically, there is a need to examine the immediate (eg, subsequent month) and 
longer term (eg, 3–6 months later) effects of musculoskeletal trauma and acute exercise changes 
on hormone reproducibility to determine the best postinjury time frame to obtain an accurate 
representation of a woman's typical hormone profile. Examining these effects in populations at 
greatest risk for ligament trauma (eg, basketball and soccer) is also important.  
 
 
WHAT IS ALREADY KNOWN ON THIS TOPIC 
Although there is a growing consensus that the risk of ACL injury varies across the menstrual 
cycle, the hormonal profile associated with a greater likelihood of injury remains unclear. 
Because ACL injuries occur infrequently, retrospective studies offer the most practical research 
design to examine hormone profiles associated with injury risk.  
 
WHAT THIS STUDY ADDS 
To initially examine the feasibility of retrospectively examining hormone profiles, month-to-
month consistency in hormone concentrations was examined in young, recreationally active 
eumonorrheic women. Results indicate that sex hormone profiles are in large part reproducible 
over two consecutive months, particularly when multiple samples are taken over consecutive 
days.  
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